Journal
VACCINE
Volume 28, Issue 28, Pages 4445-4451Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.03.062
Keywords
Recombinant human interferon alpha-2b; Randomized controlled trial; Viral respiratory infection; Nasal spray
Categories
Funding
- Ministry of Science and Technology of the People's Republic of China [2003AA208220]
Ask authors/readers for more resources
The military population has a high disease burden of acute viral respiratory infections in China. To assess the efficacy and safety of a low-dose recombinant human interferon alpha-2b (rIFN alpha-2b) nasal spray in preventing acute viral respiratory infections in military population, we performed this randomized controlled trial. The results showed that application of the rIFN alpha-2b nasal spray had the benefits in prevention of infections caused by influenza A virus, influenza B virus parainfluenza viruses 1-3 and adenovirus species B. However, no benefit was seen in preventing respiratory syncytial virus. No severe adverse events were reported. Therefore, the rIFN alpha-2b nasal spray was effective and well tolerated for preventing common viral respiratory infections in the military recruits. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available